Information on the target
CVC Capital Partners and Groupe Bruxelles Lambert (GBL) have increased their public buyout offer for the Italian pharmaceutical group Recordati to €10.5 billion (approximately $11.8 billion). This revised offer, announced on October 7, follows significant pushback from minority shareholders who believed the initial offer undervalued the Milan-listed pharmaceutical company. CVC, which already holds a controlling stake acquired in 2018 from the founding family, aims to fully delist Recordati from the Borsa Italiana.
The increased offer price per share reflects Recordati's consistent cash generation, its growing portfolio in rare diseases, and its expanding presence in emerging markets. This deal is poised to be one of the largest European delistings finalized in 2026, highlighting the increasing willingness of private equity sponsors to pay premium prices for high-quality healthcare assets with sustainable revenue streams.
Industry overview in the target’s specific country
The Proprietary & Advanced Pharmaceuticals industry in Italy has been experiencing robust growth, driven by a combination of innovative research, a strong regulatory framework, and increasing demand for specialized treatments. Italy is home to a number of leading pharmaceutical companies that focus on proprietary drugs, particularly in the areas of oncology, rare diseases, and advanced therapies. The Italian government has been supportive of pharmaceutical innovation, providing incentives for research and development, which has further propelled the industry forward.
Moreover, the Italian pharmaceutical market is characterized by a high level of investment in biotechnology and advanced therapeutics. This sector has seen a surge in venture capital funding, which has enabled companies to accelerate their product development timelines and bring new therapies to market more quickly. The presence of a skilled workforce and a strong network of research institutions also contributes to the industry's competitive advantage.
Despite facing challenges such as pricing pressures and regulatory hurdles, the Proprietary & Advanced Pharmaceuticals industry in Italy remains resilient. The increasing prevalence of chronic diseases and an aging population are driving demand for innovative treatments, making this sector an attractive investment opportunity for private equity firms. Furthermore, the ongoing shift towards personalized medicine and advanced therapies is expected to create new avenues for growth in the coming years.
As private equity firms look to capitalize on these trends, the acquisition of companies like Recordati represents a strategic move to gain exposure to high-margin, non-cyclical businesses that…